| Marie K Mayr, CRNA | |
|
14820 Physicians Ln, 242, Rockville, MD 20850-3945 | |
| (301) 838-9606 | |
| Not Available |
| Full Name | Marie K Mayr |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 25 Years |
| Location | 14820 Physicians Ln, Rockville, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922046853 | NPI | - | NPPES |
| 400896100 | Medicaid | MD | |
| 601285800 | Other | FECA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R147068 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Capitol Anesthesia Associates Ltd | 3274848320 | 19 |
News Archive
In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor.
Early structural changes in the back of the eye — now visible with a newly developed eye scan — may indicate the onset of Alzheimer's disease. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Seattle, Wash.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.
› Verified 1 days ago
| Entity Name | Ambulatory Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720192230 PECOS PAC ID: 2264320829 Enrollment ID: O20040306000100 |
News Archive
In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor.
Early structural changes in the back of the eye — now visible with a newly developed eye scan — may indicate the onset of Alzheimer's disease. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Seattle, Wash.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.
› Verified 1 days ago
| Entity Name | First Colonies Anesthesia Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740218767 PECOS PAC ID: 8426039744 Enrollment ID: O20040607001456 |
News Archive
In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor.
Early structural changes in the back of the eye — now visible with a newly developed eye scan — may indicate the onset of Alzheimer's disease. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Seattle, Wash.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.
› Verified 1 days ago
| Entity Name | Surgical Anesthesia Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811930647 PECOS PAC ID: 5890739205 Enrollment ID: O20050616000610 |
News Archive
In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor.
Early structural changes in the back of the eye — now visible with a newly developed eye scan — may indicate the onset of Alzheimer's disease. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Seattle, Wash.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.
› Verified 1 days ago
| Entity Name | Metromac Anesthesiology, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437456951 PECOS PAC ID: 0648455097 Enrollment ID: O20110428000214 |
News Archive
In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor.
Early structural changes in the back of the eye — now visible with a newly developed eye scan — may indicate the onset of Alzheimer's disease. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Seattle, Wash.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.
› Verified 1 days ago
| Entity Name | Capitol Anesthesia Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194106955 PECOS PAC ID: 3274848320 Enrollment ID: O20150818005376 |
News Archive
In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor.
Early structural changes in the back of the eye — now visible with a newly developed eye scan — may indicate the onset of Alzheimer's disease. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Seattle, Wash.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marie K Mayr, CRNA 6605 Lone Oak Dr, Bethesda, MD 20817-1649 Ph: () - | Marie K Mayr, CRNA 14820 Physicians Ln, 242, Rockville, MD 20850-3945 Ph: (301) 838-9606 |
News Archive
In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor.
Early structural changes in the back of the eye — now visible with a newly developed eye scan — may indicate the onset of Alzheimer's disease. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Seattle, Wash.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.
› Verified 1 days ago
Steven J. Zito, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 15001 Shady Grove Rd, Rockville, MD 20850 Phone: 301-340-7141 | |
Mrs. Marie Patricia Innocent, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 2101 E Jefferson St, Kaiser Permanente, Rockville, MD 20852 Phone: 301-816-7405 Fax: 540-552-2938 | |
Sally A Salvatori, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 14820 Physicians Ln, 242, Rockville, MD 20850 Phone: 301-838-9606 | |
Danielly M Muchiutti, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 15005 Shady Grove Road, Suite 200, Rockville, MD 20850 Phone: 301-340-8099 Fax: 301-340-8535 | |
Natalie Leikus Taylor, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 9901 Medical Center Dr, Rockville, MD 20850 Phone: 410-746-9580 | |
Mary C Roche, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 14820 Physicians Ln, 242, Rockville, MD 20850 Phone: 301-838-9606 | |
Amelework Tesfaye Berhe, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 4924 Arctic Terrace, Rockville, MD 20853 Phone: 202-421-6103 |